Zobrazeno 1 - 10
of 253
pro vyhledávání: '"Mary Ellen Ross"'
Autor:
Touitou, Béatrice
Publikováno v:
Revue d'Histoire littéraire de la France, 1995 Sep 01. 95(5), 807-807.
Externí odkaz:
https://www.jstor.org/stable/40532327
Autor:
E. Jane Via
Publikováno v:
Biblical Theology Bulletin: Journal of Bible and Culture. 21:78-79
Autor:
Demaris Wehr
Publikováno v:
Horizons. 16:410-412
Publikováno v:
J Psychoactive Drugs
One hundred twenty one opiate-dependent individuals in methadone maintenance treatment at an urban university medical center in the U.S. were administered the Inventory of Drug Use Consequences (InDUC), and 68 subjects provided follow-up assessments
Autor:
Patrick J. Creaven, Lakshmi Pendyala, Vladimir Badmaev, Mary Ellen Ross, Patrick F. Smith, Marwan Fakih, Joshua Prey, William E. Brady, Youcef M. Rustum
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:499-508
We conducted a phase I study to determine the recommended dose of selenomethionine (SLM) in combination with irinotecan that consistently results in a protective plasma selenium (Se) concentrations15 microM after 1 week of SLM loading.A 3-3 standard
Autor:
Mary Ellen Ross, Michael A. Caligiuri
Publikováno v:
Blood. 89:910-918
Interferon-γ (IFN-γ) is critical for an effective innate immune response against infection. A combination of interleukins (ILs) derived from activated T cells (IL-2) and monocytes (IL-12), or monocytes alone (IL-15 and IL-12), induces optimal produ
Autor:
L Sullivan, Chuan-Chu Chou, MV Seiden, Robert A. Baiocchi, S Haldar, M Monne, Mary Ellen Ross, J Sklar, SK Narula, Jian Tan
Publikováno v:
Blood. 85:1063-1074
Both human (hu) and viral (v) interleukin-10 (IL-10) appear to be important cofactors in the survival and growth of lymphoblastoid cell lines infected with Epstein-Barr virus (EBV). When mice with severe combined immune deficiency (SCID) are injected
Autor:
Borges, Jason1 jasangborges@gmail.com
Publikováno v:
Journal of Biblical Literature. 2024, Vol. 143 Issue 2, p323-337. 15p.
Autor:
Mary Ellen Ross
Publikováno v:
Neophilologus. 76:41-50
Autor:
Marwan Fakih, Karoli Toth, Lakshmi Pendyala, Alan Litwin, Julianne L. Holleran, Gerald J. Fetterly, Igor Espinoza-Delgado, Youcef M. Rustum, Merrill J. Egorin, James A. Zwiebel, Mary Ellen Ross
Purpose: We conducted a phase I study to determine the maximum tolerated dose of vorinostat in combination with fixed doses of 5-fluorouracil (FU), leucovorin, and oxaliplatin (FOLFOX). Experimental Design: Vorinostat was given orally twice daily for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a676a7b68b17abbe3bd4392d9c4375a
https://europepmc.org/articles/PMC4134938/
https://europepmc.org/articles/PMC4134938/